Apply Give

Other ways to search: Events Calendar | UTHSC

Provectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteria

Written by Communications and Marketing

|

Provectus (OTCQB: PVCT) today announced that preclinical research on the Company’s pharmaceutical-grade rose bengal sodium drug substance against colistin-resistant gram-negative (G-) bacteria was published in The Journal of Antibiotics, a medical periodical by Nature Portfolio for the Japan Antibiotics Research Association. Colistin is used as a last-resort treatment for infections when other drugs fail. The World Health Organization (WHO) classifies colistin as “highest priority critically important for human health.” Led by Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences, College of Pharmacy, this research work was conducted under a sponsored research agreement between the University of Tennessee Health Science Center in Memphis and Provectus.

Top Publishers